View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 18, 2022

Sciwind commences dosing in Phase IIb obesity drug trial

The trial will be carried out in Australia and New Zealand, and will enrol nearly 200 patients with obesity.

Sciwind Biosciences has announced the start of participant dosing in its Phase IIb trial of its lead glucagon-like peptide-1 (GLP-1) drug candidate, XW003, in individuals with obesity.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The GLP-1 analogue XW003 was found to be safe and well-tolerated, and elicited a dose-based drop in weight in prior trials.

The randomised, multicentre, open-label, active-controlled trial will analyse a once-weekly subcutaneous dose of XW003.

Set to be carried out in Australia and New Zealand, the trial will enrol nearly 200 subjects with obesity, who will receive the treatment with XW003 for up to 26 weeks.

The participants will also be followed up for another five weeks without any treatment.

Assessment of tolerability, safety and efficacy of XW003 treatment in obese subjects is the aim of the trial. Top-line results are anticipated in the second half of this year

The drug candidate XW003 is also being analysed in another trial underway in China enrolling patients with obesity.

Sciwind founder and CEO Dr Hai Pan said: “Initiation of patient dosing in this multicentre, international study for the treatment of obesity is another important milestone for the company and a strong testament to our team’s dedication and capability. 

“We are committed to continuing the development of XW003, as well as other drug candidates in Sciwind’s pipeline, for the treatment of metabolic diseases, including obesity, diabetes, and NASH.”

The clinical-stage biopharmaceutical company focuses on discovery and development of new treatments for metabolic diseases. 

Sciwind has investigated several technologies, such as oral peptide and inhaled protein therapeutics delivery platforms and identified a sequence of therapy candidates based on these technologies. 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena